Pasteurellosis caused by Pasteurella multocida is an important bacterial disease in rabbits. Infected rabbits are unsuitable for research involving respiratory, genital, and sensory systems because of colonization by the organism and lesions in these systems (17) .
One approach to control and eliminate pasteurellosis in rabbits is to develop an effective and safe vaccine. Live mutant P. multocida vaccines and P. multocida subunit vaccines have been developed and evaluated for their efficacy in preventing the disease. Rabbits immunized with a streptomycin-dependent live mutant vaccine (17) , KSCN extracts (25) , or outer membranes of P. multocida (17a) developed resistance against homologous challenge. Further, rabbit immune serum against the KSCN extract of P. multocida passively protected rabbits against homologous challenge (18) . Since rabbits mounted immune responses to these vaccines and the immune serum passively protected rabbits against the homologous challenge (18), it is concluded that the antigens identified by these immune sera are immunogenic in rabbits and are potential vaccine candidates. At least 15 protein immunogens were identified by radioimmunoprecipitation (RIP) and Western blot (immunoblot) analysis with various rabbit immune sera (15) . However, only a subset of these immunogens which are exposed on the cell surface and are antibody accessible has a great potential to be protective immunogens. We have identified five such P. multocida outer membrane proteins with molecular masses of 27, 37.5, 49.5, 58.7, and 64.4 kDa by whole-cell RIP (WC-RIP). The 37.5-kDa protein appears to be the major outer membrane protein (15) . * Corresponding author.
To define and characterize these specific surface outer membrane antigens, we produced and characterized murine monoclonal antibodies (MAbs) to a virulent strain of P. multocida of rabbit origin. Characterization of MAbs in terms of chemical characteristics of the binding site, specificity of the epitope, cell surface exposure, accessibility of the epitope, and protection in rabbits and mice provides preliminary information for the identification of the protective immunogens of P. multocida. The results of the study showed that MAb 1608, directed to the 37.5-kDa outer membrane protein, protects rabbits and mice.
MATERIALS AND METHODS
Bacterial strains and culture media. P. multocida UT-1, isolated from a rabbit with suppurative rhinitis, was used in most of the experiments. The P. multocida organisms were grown on blood agar plates inoculated with lyophilized stock and then in brain heart infusion broth (Difco Laboratories, Detroit, Mich.) at 37°C. All P. multocida cultures were harvested in the log phase of growth and used for experiments. Other P. multocida rabbit strains used in adsorption and mouse challenge experiments were strain 81-291 (serotype NT:3,7), isolated from a rabbit with tympanitis; strain 81-556 (serotype NT: 10, 12) , from a rabbit with pneumonia; strain 84-439 (serotype NT:3,10), from a rabbit with rhinitis; strain 85-763 (serotype A:3,10), from a rabbit with rhinitis; and strain 86-313 (serotype D: 3, 10) , from a rabbit with pyometritis.
Preparation of P. multocida outer membrane vesicles. Outer membrane vesicles were prepared by a modification of the method of McDade and Johnston (20) . The protein was examined qualitatively by sodium dodecyl sulfate-polyacryl-amide gel electrophoresis (SDS-PAGE), and the concentration was determined by the modified Lowry procedure (2) . These outer membrane vesicles were used as antigens in immunizing mice and in enzyme-linked immunosorbent assay (ELISA) and Western blot analyses.
Animals. Pasteurella-free New Zealand White female rabbits, weighing 2.7 to 3.6 kg, were purchased from HazletonDutchland Laboratories, Denver, Pa. All rabbits were determined to be free of P. multocida infection when there were two negative P. multocida cultures from the nasal cavity and serum immunoglobulin G (IgG) antibody was negative against P. multocida by ELISA (18) . Six-to eight-week-old BALB/c female mice (Jackson Laboratories, Bar Harbor, Maine) free of murine microbial pathogens, including viruses, bacteria, mycoplasma, and parasites, were used for production of MAbs and protection studies. The murine pathogens tested were ectromelia virus, GD VII virus, lymphocytic choriomeningitis virus, minute virus of mice, mouse adenovirus, mouse hepatitis virus, mouse rotavirus, murine cytomegalovirus, polyomavirus, reovirus 3, Sendai virus, Mycoplasma arthritidis, Mycoplasma pulmonis, Salmonella spp, P. multocida, Bordetella bronchiseptica, Syphacia obvelata, Aspiculuris tetraptera, Spironucleus muris, and mites.
MAb production. MAb 1608 was produced from a mouse immunized (twice at 2-week intervals) intraperitoneally with 50 jig of purified P. multocida outer membrane mixed with complete Freund's adjuvant. Twenty-five micrograms of P. multocida outer membrane in phosphate-buffered saline (PBS) was injected intravenously 3 days prior to a fusion. Immunized mice which produced ELISA antibodies directed against outer membrane vesicles of P. multocida were used for hybridoma production as described previously (26), with modification.
SP2/0-nonsecreting mouse myeloma cells were grown in Dulbecco modified Eagle medium (DMEM; GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% heatinactivated fetal calf serum, 2 mM L-glutamine, and 50 U of penicillin-streptomycin (GIBCO) per ml. Immune spleen cells (108) from an immunized BALB/c mouse were mixed with 2 x 107 SP2/0 cells and centrifuged (40C) at 270 x g. The cell pellet was then warmed at 37°C and mixed with DMEM containing 35% polyethylene glycol (molecular weight, 1,000; BDH Chemicals, Poole, England) and 10% dimethyl sulfoxide (Sigma Chemical Co., St. Louis, Mo.) for 1.5 min. The cell suspension was centrifuged at 270 x g, and the supernatant was discarded. The final cell pellet was resuspended in DMEM-HY medium (26) and plated out into 96-well tissue culture plates (Costar, Data Packaging Corp., Cambridge, Mass.) at 50 ,u.l per well. The plates were incubated in a 37°C incubator containing 5% CO2. On day 2, a 50-,lI portion of a twofold concentration of Littlefield HAT selection medium (14) was added to each well. On day 4, an additional 100-,ul portion of HAT medium was added to each well. Approximately 7 to 10 days after fusion, hybridoma colonies became visible. After day 7, all wells were fed DMEM-HT-glycine medium (26) . These colonies were expanded into 2 wells in a 96-well plate. If growth continued, cells from 2 wells of a 96-well plate were expanded into 1 well of a 24-well plate. Culture supernatants from the 24-well plate were then analyzed for antibody activities directed against P. multocida outer membrane antigens by ELISA and Western blot. Hybridoma cells producing the desired antibodies were cloned by limiting dilution (6) (18) , using P. multocida outer membrane vesicles as antigens. The membrane antigens were separated by SDS-PAGE and transferred to nitrocellulose paper (NCP) by the methanol-Tris glycine method (27) . After transfer, the NCP strips were incubated with PBS-T containing 2% BSA for 1 h at room temperature to block the nonspecific binding sites. The NCP strips were then incubated with hybridoma culture supernatant (1:2 dilution in PBS-T) overnight at 4°C and washed three times with PBS-T at the end of incubation. The NCP was next reacted with a 1:1,000 dilution (in PBS-T) of horseradish peroxidase-conjugated goat anti-mouse IgG (heavy and light chains specific; Cappel) for 8 h at 4°C, washed three times (15 min each) with PBS-T, and incubated with a 1:1,000 dilution of a horseradish peroxidase conjugate of rabbit anti-goat IgG (Cappel) overnight at 4°C. The strips were then washed three times in PBS-T and immersed in 50 mM Tris buffer (pH 7.4) containing 4-chloro-1-naphthol (0.5 mg/ml) and hydrogen peroxidase (0.01%) for color development. The color reaction was terminated by flooding the NCP with distilled water.
WC-RIP. Selected hybridoma culture supernatants positive by ELISA and Western blot analysis were further characterized by WC-RIP to confirm the antibody specificity. Briefly, mixtures containing 125I-labeled P. multocida cells (2 x 108 cpm/ml), hybridoma culture supernatant, SP2/0 culture supernatant (medium control), or PBS in Eppendorf tubes were incubated on a rocking platform for 1 SDS-PAGE. The SDS-PAGE procedure of Laemmli (13) was used. The samples were run by discontinuous SDS-PAGE in 1.5-mm-thick slab gels. A 4% (wt/vol) polyacrylamide stacking gel and a 10% (wt/vol) polyacrylamide separating gel were used to separate the distinct proteins into bands. Electrophoresis was conducted at a 30-mA constant current per gel at 4°C until the pyronin Y tracking dye entered the separating gel; the constant current was then increased to 45 mA per gel. The protein contents of samples were measured by the method of Bradford (2) with Bio-Rad reagent (Bio-Rad Laboratories, Richmond, Calif.). Samples were boiled with digestion buffer containing 5% (vol/vol) 2-mercaptoethanol prior to being loaded onto the gel. Labeled proteins on the gel were fixed, stained with Coomassie blue, destained, dried, and identified by autoradiography (9 Preparation of LPS of P. multocida. Lipopolysaccharide (LPS) was extracted from P. multocida (strain UT-1) by using a hot phenol-water procedure described previously (24 (19) . For pathologic evaluation, the nasal turbinates, lungs (all lobes), and tympanic bullae were prepared for routine histopathologic examination (19) . Microscopic lesions of nasal turbinates (three sections), lungs (five sections), and tympanic bullae (two sections) from each rabbit were scored as 0 (normal), 1 (mild), 2 (moderate), or 3 (severe). To compare scores, the sum of lesion scores for each organ from individual rabbits within a group was divided by the sum of the maximum possible scores to determine the group lesion index (GLI). A GLI of 1.0 indicates the most severe lesions possible for a group.
Immunoprotective studies in mice. A kinetic study was performed to determine the optimal time of immunoprotection afforded by MAb 1608. Sixty-eight female BALB/c mice were divided into two groups (see Table 3 ). Mice lacking the 37.5-kDa antigenic determinant. In each experiment, BALB/c female mice were divided into two groups (see Table 4 ). Mice from groups 1 and 2 were anesthetized with methoxyflurane, inoculated i.n. with 50 ,ul of affinitypurified MAb containing 16 ,ug of protein or with SP2/0 culture supernatants, respectively (MAb and SP2/0 grown in a medium without antibiotics), allowed to recover from the anesthesia for 2 h, challenged i.n. with live P. multocida (2 x 106 CFU), and killed by methoxyflurane overdose 48 h postchallenge. Lungs were collected and homogenized to determine numbers of P. multocida as described above.
Statistical analysis. Analysis of variance was applied to determine significant differences in numbers of P. multocida in lungs and in nasal cavities among the groups of rabbits. The chi-square test was used to determine significant differences in mortality and prevalence of P. multocida colonization in nonrespiratory organs among the groups of rabbits. Student's t test was applied to determine significant differences in the numbers of P. multocida in lungs of mice (28) . RESULTS Molecular specificity of MAb 1608. We used WC-RIP and Western blot analysis to determine the molecular mass of the antigen reactive to MAb 1608, which is of the IgG2a isotype. MAb 1608 reacted with an antigen with an estimated molecular mass of 37.5 kDa (Fig. 1, lane A) (Fig. 4, (i) Clinical criteria. Mean survival time (days) and mortality were compared among the groups ( Table 1 ). The mean survival time was increased significantly (P < 0.002) from 6.7 days (group 1) to 11.8 days (group 2). The mortality rate was reduced significantly (P < 0.025) from 100% (group 1) to 33% (group 2).
(ii) Pathological criteria. The prevalence and severity of lesions in lungs, nasal cavities, and tympanic bullae were compared among the groups ( Table 1 ). The prevalences of pneumonia were 100% (nine of nine), 67% (six of nine), and 100% (six of six) for groups 1, 2, and 3, respectively, and the differences were not significant among the groups. The severity of pneumonia as measured by GLI was reduced significantly (P < 0.001) from 0.98 (group 1) to 0.32 (group 2). No significant difference (P > 0.1) in the GLIs for pneumonia was noted between groups 1 and 3. The prevalences of rhinitis were 56% (five of nine), 11% (one of nine), and 33% (two of six) for groups 1, 2, and 3, respectively, and the differences were not significant among the groups. Similarly, the mean GLIs for rhinitis in groups 1, 2, and 3 were not significantly different. The prevalences of tympanitis were 0% (zero of nine), 11% (one of nine), and 17% (one of six) for groups 1, 2, and 3, respectively, and the differences were not significant among the groups. Similarly, the mean GLIs for tympanitis were A kinetic study showed that optimal protection, as defined by the lowest number of P. multocida organisms in lungs, was achieved at 48 h after i.n. homologous challenge (Table  3) . Consequently, mice inoculated with MAb 1608 and challenged were killed at 48 h postchallenge to determine the protective efficacy of MAb 1608 against various P. multocida strains.
Passive immunization of mice with purified MAb 1608 significantly reduced (P < 0.001) the number of P. multocida in lungs of mice which were challenged with the homologous UT-1 strain (Table 4 , experiment 1). Significant protection (P < 0.002 and P < 0.005) was also observed in mice immu- a Each rabbit was inoculated i.n. with affinity-purified MAb 1608, SP2/0 supernatants, or MAb 6G6 (1 mg per rabbit per time) at 2 h prior to and 12 and 24 h after i.n. challenge with 2 x 107 CFU of the virulent homologous P. multocida strain and killed at day 14 postchallenge. MAb 1608 is directed against the 37.5-kDa P. multocida outer membrane protein, and MAb 6G6 is directed against M. pulmonis. SP2/0 supernatants contain no antibody. MAb 1608 and MAb 6G6 are of the IgG2a isotype. SP2/0 served as a medium control, and MAb 6G6 served as an antibody specificity control.
b Number positive/number sampled; values in parentheses are percentages. cRepresents mean of the log of geometric mean CFU per nasal swab or per gram of lung tissue. The geometric mean CFU per nasal swab or per gram of lung in each rabbit was calculated and converted to the logarithmic number. The mean and standard error of the mean of the log of the geometric mean of the group was then calculated.
d The group mean in logarithmic units was converted to the geometric mean CFU per nasal swab or per gram of lung tissue. e At necropsy, a small piece of the liver, spleen, and uterus and swabs collected from the left and right tympanic bullae were inoculated onto blood agar plates for isolation of P. multocida.
f Mean CFU significantly less (P < 0.005) than for group 1. (10, 11) . The MAb against phosphocholine of the streptococcal cell wall protected mice against Streptococcus pneumoniae infection (3). Similarly, the MAb against a 98-kDa outer membrane protein of Haemophilus influenzae type b protected infant rats against homologous challenge (11) .
The MAb 1608-recognized epitope, as determined by WC-RIP and Western blot analysis, is exposed on the cell surface and is antibody accessible (Fig. 1 to 3 f Number of mice with P. multocidalnumber of mice challenged. 9 Mean of the log of the geometric mean CFU per gram of lung tissue. The geometric mean CFU per gram of lung in each mouse was calculated and converted to the logarithmic number. The mean of the log of the geometric mean of the group was then calculated. heterologous P. multocida strain lacking the antigenic determinant, the antibody activity was not removed by adsorption or recovered by elution.
That the binding site for MAb 1608 is protein in nature (Fig. 4) is consistent with the observation that this MAb was nonreactive against purified LPS obtained from the homologous P. multocida strain. Since LPS and outer membrane proteins of some gram-negative bacteria bind strongly (7), RIP analysis of labeled P. multocida cells may result in the identification of labeled membrane proteins nonspecific to the MAb. We confirmed the RIP results with Western blot analysis and eliminated the possibility that this MAb binds to an LPS molecule which has a strong affinity for outer membrane protein (7) .
We demonstrated that IgG antibodies against P. multocida play an important role against pasteurellosis in rabbits and mice. MAb 1608, with a mouse IgG2a isotype, significantly reduced the severity of pneumonia and number of P. multocida organisms in the lungs of rabbits challenged homologously. Similarly, we showed that rabbit immune serum, containing high levels of IgG antibody and negligible amounts of IgA antibody against P. multocida, significantly reduced the prevalence and severity of pneumonia and number of P. multocida organisms in the lungs of rabbits challenged homologously (18) . These results show that IgG antibodies against P. multocida play an important role in protection against lower respiratory tract infection in rabbits. That IgG antibodies play a protective role in rabbits is further strengthened by the results (Table 2) showing significant reduction of the number of P. multocida organisms in nasal cavities and the prevalence of P. multocida colonization in nonrespiratory organs. Similarly, rabbits treated with rabbit immune serum containing a high level of IgG and negligible amount of IgA antibodies resulted in a significant reduction in the prevalence of P. multocida colonization in nonrespiratory organs (18) . It is evident that IgG antibodies against P. multocida played an important role in preventing lower respiratory tract and systemic infections in most of the rabbits. MAb 1608 also played an important role in protecting mice against pulmonary infections caused by P. multocida (Tables 3 and 4) .
Mice infected experimentally with P. multocida are used extensively to study the protective efficacy of vaccines, antibody-and cell-mediated immune protection, pathogenesis, and host-parasite interactions (1, 4, 21) . In addition, P. multocida isolates which are virulent in rabbits were also virulent in mice (22) . In this study, we demonstrated that MAb 1608, which protects rabbits, also protects mice against homologous P. multocida challenge. Subsequently, we showed that MAb 1608 also protects mice against heterologous P. multocida challenges. We conclude that MAb 1608-mediated protection is antigen specific, because passive protection was shown only in mice receiving MAb 1608 and challenged with homologous or heterologous P. multocida strains bearing the antigenic determinant recognized by MAb 1608. No protection was evident in mice receiving MAb 1608 and challenged with a P. multocida strain lacking the antigenic determinant specified by MAb 1608. Furthermore, a MAb directed to an unrelated antigen (M. pulmonis) provided no protection in mice and rabbits against P. multocida challenge.
In challenge experiments, we observed that MAb 1608 provided a higher magnitude of protection in mice challenged homologously than in those challenged with a heterologous strain bearing the same antigenic determinant as that recognized by MAb 1608. This difference suggests that the heterologous strain possesses a different virulence factor(s) which is absent or nonfunctional in the homologous strain, and the different virulence factor(s) may contribute to the higher number of P. multocida organisms in the lungs. In addition, the difference in the level of protection against heterologous challenge could be related to the surface density of the 37.5-kDa antigen in various heterologous strains. That MAb 1608 significantly protected rabbits and mice against P. multocida infection is encouraging, particularly in view of the fact that this antibody is directed against a single antigenic determinant of the 37.5-kDa outer membrane protein. It is likely that monospecific polyclonal antibodies directed against multiple antigenic determinants on the 37.5-kDa protein would provide more effective protection in animals.
This study indicates that the P. multocida outer membrane protein with an estimated molecular mass of 37.5 kDa is the target of a protective MAb. We anticipate that this protective MAb will facilitate the purification of the 37.5-kDa outer membrane protein and testing of its ability to elicit protective antibodies in rabbits.
